Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
ClinicalTrials.gov Identifier: NCT01658878.
ClinicalTrials.gov Identifier: NCT01658878.
Abstract Hepatocellular carcinoma (HCC) accounts for about 90% of all primary liver cancers and is the second leading cause of cancer-related deaths worldwide. The hypervascular...
h-index: Number of publications with at least h citations each.